Viruses (Dec 2021)

ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection

  • Pragya D. Yadav,
  • Sanjeev Kumar Mendiratta,
  • Sreelekshmy Mohandas,
  • Arun K. Singh,
  • Priya Abraham,
  • Anita Shete,
  • Sanjay Bandyopadhyay,
  • Sanjay Kumar,
  • Aashini Parikh,
  • Pankaj Kalita,
  • Vibhuti Sharma,
  • Hardik Pandya,
  • Chirag G. Patel,
  • Mihir Patel,
  • Swagat Soni,
  • Suresh Giri,
  • Mukul Jain

DOI
https://doi.org/10.3390/v13122424
Journal volume & issue
Vol. 13, no. 12
p. 2424

Abstract

Read online

We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.

Keywords